REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
News

Sheba Medical Center Offers CAR-T Cell Therapy to Patients with Acute Myelogenous Leukemia (AML)

CAR-T Cell Therapy for AML Patients Has Been Developed at Sheba
Since 2016, cutting-edge CAR-T Cell Therapy in Israel has been provided at Sheba as a treatment for leukemia (ALL) and lymphoma (NHL). Now, the Tel HaShomer hospital offers CAR-T therapy for patients with multiple myeloma. As part of a clinical trial, Sheba is also the first medical facility worldwide to pioneer the use of CAR-T cell therapy to treat acute myelogenous leukemia (AML) with 8;21 translocation and CD19 expression. Cancer patients who had exhausted all lines of treatment face a promising new option.

CAR-T cell therapy is a revolutionary, individualized immune cell therapy used to treat cancer. To administer this state-of-the-art treatment at Sheba Medical Center, a doctor first extracts blood from the patient and sends it to the on-site Oncology Training Laboratories. Presently, Sheba is the only center in Israel that has a lab for preparing and engineering CAR-T cells.

At this highly specialized lab, the T-cells, a type of immune cell, are separated from the rest of the blood cells and genetically engineered to produce CARs (chimeric antigen receptors). The modified T-cells are given time to multiply in the laboratory until there is a sufficient amount to inject back into the patient. Now though, as a result of the CARs, the T-cells behave differently – they are programmed with the ability to identify, target, and destroy tumor cells.

While the T-cells reproduce in Sheba’s laboratory, chemotherapy is delivered to the patient to suppress their immune system. This is done to help maximize the efficiency of the modified T-cells once they are injected into the patient. Altogether, the CAR-T cell therapy process takes approximately 10 days, and patients generally remain hospitalized for about two weeks for observation.

The first child with leukemia to be treated with CAR-T cell therapy in Israel achieved total remission. Since then, the success rates for achieving remission have been 85-90% in young children, approximately 80% in teenagers, and approximately 70% in the total adult population.

In October 2019, a ceremony was held to mark 130 patients treated with CAR-T cell therapy at Sheba Medical Center. In the words of Prof. Yitzhak Kreiss, Director of Sheba Medical Center, “[This] ceremony represents a transition from vision to courage – the creation of a world where CAR-T cell therapy becomes a standard part of the institutional care we offer to patients. This treatment is a connection between science and research, between laboratory capabilities and regulation, and most importantly – between all of the above and the patient. That’s our wonderful story – a tale of partnership and progress.”

Now, Sheba is excited to promote the availability of CAR-T cell therapy for patients with multiple myeloma. Additionally, patients with acute myelogenous leukemia (AML) with 8;21 translocation and CD19 expression, can receive the immune cell therapy as part of a clinical trial at Sheba. Sheba is the first and currently the only medical center in the world to offer CAR-T therapy for AML.

arnon nagler
Prof. Arnon Nagler

Prof. Arnon Nagler, Director of Hematology, announces, “The ground-breaking CAR-T treatment that was applied at Sheba for over 130 patients suffering from ALL or NHL, is now approved for use in patients with multiple myeloma as part of a clinical trial. Moreover, Sheba is the first medical center in the world to pioneer CAR-T therapy application for AML patients with 8;21 translocation and CD19 expression. Patients interested in undergoing this innovative treatment at Sheba will be offered a full diagnostic procedure to determine whether this treatment is a suitable option for them.”

Related
Sheba DUNS 100

For The Second Consecutive Year: Sheba Tops the Healthcare Sector on Dun & Bradstreet’s List of Leading Organizations

Dun & Bradstreet, the world’s foremost commercial data company, ranked 71 doctors from Sheba Medical Center in its list of the top Israeli clinical experts.…
Read More

Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More